CA2761777A1 - Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy - Google Patents

Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy Download PDF

Info

Publication number
CA2761777A1
CA2761777A1 CA2761777A CA2761777A CA2761777A1 CA 2761777 A1 CA2761777 A1 CA 2761777A1 CA 2761777 A CA2761777 A CA 2761777A CA 2761777 A CA2761777 A CA 2761777A CA 2761777 A1 CA2761777 A1 CA 2761777A1
Authority
CA
Canada
Prior art keywords
her2
cell
activation
p95her2
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2761777A
Other languages
English (en)
French (fr)
Inventor
Phillip Kim
Xinjun Liu
Richard Kirkland
Tani Lee
Belen Ybarrondo
Sharat Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierian Holdings Inc
Original Assignee
Prometheus Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometheus Laboratories Inc filed Critical Prometheus Laboratories Inc
Publication of CA2761777A1 publication Critical patent/CA2761777A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2761777A 2009-05-14 2010-05-13 Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy Abandoned CA2761777A1 (en)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US17845809P 2009-05-14 2009-05-14
US61/178,458 2009-05-14
US18078709P 2009-05-22 2009-05-22
US61/180,787 2009-05-22
US18724609P 2009-06-15 2009-06-15
US61/187,246 2009-06-15
US22852209P 2009-07-24 2009-07-24
US61/228,522 2009-07-24
US23564609P 2009-08-20 2009-08-20
US61/235,646 2009-08-20
US24180409P 2009-09-11 2009-09-11
US61/241,804 2009-09-11
US26285609P 2009-11-19 2009-11-19
US61/262,856 2009-11-19
US26522709P 2009-11-30 2009-11-30
US61/265,227 2009-11-30
PCT/US2010/034814 WO2010132723A1 (en) 2009-05-14 2010-05-13 Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy

Publications (1)

Publication Number Publication Date
CA2761777A1 true CA2761777A1 (en) 2010-11-18

Family

ID=42315848

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2761777A Abandoned CA2761777A1 (en) 2009-05-14 2010-05-13 Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy

Country Status (7)

Country Link
US (1) US9726669B2 (enExample)
EP (1) EP2430443B1 (enExample)
JP (1) JP5718319B2 (enExample)
AU (1) AU2010248884B2 (enExample)
CA (1) CA2761777A1 (enExample)
NZ (2) NZ596468A (enExample)
WO (1) WO2010132723A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120295259A1 (en) 2011-05-19 2012-11-22 Laboratory Corporation Of America Holdings Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients
US11401344B2 (en) 2008-12-01 2022-08-02 Laboratory Corporation Of America Holdings Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients
RU2558931C2 (ru) 2010-01-12 2015-08-10 Нестек С.А. Способы предсказания ответа трижды негативного рака молочной железы на терапию
SG191230A1 (en) 2010-12-23 2013-07-31 Nestec Sa Drug selection for malignant cancer therapy using antibody-based arrays
MX343327B (es) 2011-02-17 2016-11-01 Nestec Sa Ensayos para detectar autoanticuerpos contra farmacos anti-tnfa.
BR112013020992A2 (pt) 2011-02-17 2016-10-11 Nestec Sa aparelho e método para isolamento de leucócitos e células tumorosas por meio de filtração
EP2681552A2 (en) 2011-03-02 2014-01-08 Nestec S.A. Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures
KR20140020318A (ko) 2011-04-04 2014-02-18 네스텍 소시에테아노님 위암 환자의 생존률 예측 및 개선 방법
CA3295783A1 (en) 2011-05-10 2026-03-02 Prometheus Laboratories, Inc. Methods of disease activity profiling for personalized therapy management
WO2012154935A1 (en) * 2011-05-12 2012-11-15 Eisai R&D Management Co., Ltd. Biomarkers that are predictive of responsiveness or non-responsiveness to treatment with lenvatinib or a pharmaceutically acceptable salt thereof
KR101851425B1 (ko) 2011-09-02 2018-04-23 네스텍 소시에테아노님 치료 효능 결정을 위한 신호 경로 단백질의 프로파일링
EP2788752B1 (en) 2011-12-05 2018-10-03 Pierian Holdings, Inc. Method of therapy selection for patients with lung cancer
EP2605014A1 (en) * 2011-12-16 2013-06-19 Merck Patent GmbH General strategy for antibody library screening
US20130330761A1 (en) 2012-06-12 2013-12-12 Celcuity, LLC Whole cell assays and methods
EP2863920B1 (en) 2012-06-20 2023-03-22 Eutropics Pharmaceuticals, Inc. Quinoline derivatives for use in the tratment of breast cancer
ES2638971T3 (es) 2012-10-05 2017-10-24 Nestec S.A. Métodos para predecir y monitorizar la cicatrización de la mucosa
EP2922544B1 (en) 2012-11-21 2018-08-01 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
US20140221368A1 (en) * 2013-02-01 2014-08-07 Meso Scale Technologies, Llc Biomarkers of therapeutic responsiveness
HK1218939A1 (zh) 2013-02-05 2017-03-17 Nestec S.A. 用於非小细胞肺癌疗法的药物选择
EP2954328A1 (en) 2013-02-05 2015-12-16 Nestec S.A. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
WO2014122600A1 (en) 2013-02-05 2014-08-14 Nestec S.A. Methods of selecting combination therapy for colorectal cancer patients
JP6202362B2 (ja) * 2013-03-04 2017-09-27 国立大学法人北海道大学 乳癌乳房温存療法後の局所再発リスクの予測に用いるための診断薬並びに予測方法
EP3373010A1 (en) 2013-05-21 2018-09-12 Pierian Holdings, Inc. Method for selecting a therapy for the treatment of colorectal cancer patients
US10732182B2 (en) 2013-08-01 2020-08-04 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
WO2015028974A2 (en) 2013-08-30 2015-03-05 Nestec S.A. Polyp recurrence
AU2014342269B2 (en) 2013-10-30 2020-02-27 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
WO2015083085A1 (en) 2013-12-03 2015-06-11 Nestec S.A. Signaling pathways in tissues from inflammatory bowel disease patients
WO2015089380A2 (en) 2013-12-12 2015-06-18 Celcuity Llc Assays and methods for determining the responsiveness of an individual subject to a therapeutic agent
JP6666852B2 (ja) * 2014-01-16 2020-03-18 イルミナ インコーポレイテッド 前立腺がん再発の予後に関する遺伝子発現パネル
WO2015110989A1 (en) 2014-01-23 2015-07-30 Nestec S.A. Biomarker panel for assessment of mucosal healing
KR101527797B1 (ko) 2014-06-03 2015-06-15 한국과학기술원 신호전달경로의 활성화 상태 분석방법 및 이를 이용한 개인 맞춤형 치료제의 선정방법
MX2017004742A (es) 2014-10-20 2017-07-20 Nestec Sa Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos.
EP3699589A1 (en) * 2014-12-12 2020-08-26 Celcuity Inc. Methods of measuring erbb signaling pathway activity to diagnose and treat cancer patients
WO2016115105A1 (en) 2015-01-12 2016-07-21 Eutropics Pharmaceuticals, Inc. Context dependent diagnostics test for guiding cancer treatment
JP2015127711A (ja) * 2015-02-10 2015-07-09 公立大学法人横浜市立大学 初期乳癌の検出方法
CN104762264A (zh) * 2015-04-20 2015-07-08 安徽安科生物工程（集团）股份有限公司 曲妥珠单抗耐药的人乳腺癌细胞株及其制备方法和应用
CN109789204A (zh) * 2016-05-31 2019-05-21 雀巢产品技术援助有限公司 基于her2和her3通路亚型选择乳癌患者药物疗法的方法
CN109843926B (zh) 2016-09-30 2023-01-20 豪夫迈·罗氏有限公司 针对cd3的双特异性抗体
EP3879269A3 (en) 2017-03-20 2021-11-17 Celcuity Inc. Methods of measuring signaling pathway activity for selection of therapeutic agents
KR20200009095A (ko) 2017-05-31 2020-01-29 프로메테우스 바이오사이언시즈, 인크. 크론병 환자에서 점막 치유를 평가하는 방법
WO2019126168A1 (en) * 2017-12-21 2019-06-27 Proplex Technologies, LLC Sensitive detection of g-protein coupled receptor-associated sorting protein 1 (gasp-1). gasp-1 microvesicles, and gasp-1 exosomes
WO2021108043A1 (en) 2019-11-27 2021-06-03 University Of Cincinnati Assessing treatment response with estimated number of tumor cells
CN119614505B (zh) * 2023-09-12 2025-12-05 珠海圣美生物诊断技术有限公司 稀有细胞捕获试剂组合及方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US6541214B1 (en) 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7695926B2 (en) 2001-07-10 2010-04-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting receptor-ligand interactions in single cells
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20040229380A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
US7402397B2 (en) 2002-05-21 2008-07-22 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
WO2004000102A2 (en) 2002-06-19 2003-12-31 Abgenix, Inc. Method for predicting response to epidermal growth factor receptor-directed therapy
HUP0600340A3 (en) 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
ATE442589T1 (de) 2002-07-25 2009-09-15 Aclara Biosciences Inc Nachweis der rezeptoroligomerisierung
BRPI0408928A (pt) 2003-04-01 2006-09-12 Monogram Biosciences Inc métodos para determinar uma situação de doença em um paciente, uma situação apoptótica de células em uma amostra, e uma situação de um cáncer em um paciente
US7402398B2 (en) 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
US20100291594A1 (en) 2003-07-17 2010-11-18 Laboratory Corporation Of America Holdings ErbB Surface Receptor Complexes as Biomarkers
WO2005011607A2 (en) 2003-08-01 2005-02-10 Smithkline Beecham Corporation Treatment of cancers expressing p95 erbb2
WO2005037071A2 (en) * 2003-10-14 2005-04-28 Monogram Biosciences, Inc. Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
JP5422120B2 (ja) 2004-05-27 2014-02-19 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト 癌患者による上皮成長因子受容体阻害薬に対する臨床転帰の予測方法
WO2006044748A2 (en) 2004-10-15 2006-04-27 Monogram Biosciences, Inc. RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
CN104198705B (zh) * 2006-09-21 2017-06-09 雀巢产品技术援助有限公司 检测稀有循环细胞内多种信号转导分子的基于抗体的阵列
WO2008109332A2 (en) 2007-03-01 2008-09-12 Targeted Molecular Diagnostics, Llc Methods and compositions for determining the efficacy of breast cancer therapeutics
WO2008127707A1 (en) 2007-04-13 2008-10-23 Dana Farber Cancer Institute, Inc. Receptor tyrosine kinase profiling
US20090017050A1 (en) 2007-07-13 2009-01-15 Ventana Medical Systems, Inc. Egfr antigen-binding molecules and uses thereof
NZ582618A (en) * 2007-07-13 2012-07-27 Prometheus Lab Inc Drug selection for lung cancer therapy using antibody-based arrays
AU2008317404B2 (en) 2007-10-19 2014-12-18 Cell Signaling Technology, Inc. Cancer classification and methods of use
WO2009086197A1 (en) 2007-12-20 2009-07-09 Monogram Biosciences, Inc. Her-2 diagnostic methods
ES2553390T3 (es) * 2008-02-25 2015-12-09 Nestec S.A. Método para la detección de receptores truncados intracelulares
ES2342646B1 (es) 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
EP2438442B1 (en) * 2008-12-01 2017-08-09 Laboratory Corporation of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
BRPI1007321A2 (en) 2009-01-15 2018-07-10 Laboratory Corporation Of America Holdings methods for measuring and / or quantifying the presence and / or amount of her-3 or her-3 in a complex in a patient sample, and to determine if an individual with cancer is likely to respond to treatment with a targeted therapy. and antibody.
US20100332417A1 (en) 2009-06-02 2010-12-30 Targeted Molecular Diagnostics, Llc Methods for the detection and quantitation of the p95 component of her2/neu (erbb2)
EP2473854B1 (en) 2009-06-23 2017-08-23 Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud Systems and methods for treating, diagnosing and predicting the response to therapy of breast cancer
WO2011031982A1 (en) 2009-09-10 2011-03-17 Myriad Genetics, Inc. Methods and compositions for predicting cancer therapy response
EP2330131B1 (en) 2009-12-07 2014-10-08 Fundació Privada Institució Catalana De Recerca I Estudis Avancats Antibodies against HER2 truncated variant CTF-611

Also Published As

Publication number Publication date
US20110071042A1 (en) 2011-03-24
AU2010248884B2 (en) 2015-04-02
WO2010132723A1 (en) 2010-11-18
EP2430443B1 (en) 2018-06-27
JP5718319B2 (ja) 2015-05-13
NZ596468A (en) 2013-11-29
EP2430443A1 (en) 2012-03-21
AU2010248884A1 (en) 2012-01-12
US9726669B2 (en) 2017-08-08
JP2012526992A (ja) 2012-11-01
NZ616755A (en) 2015-05-29

Similar Documents

Publication Publication Date Title
AU2010248884B2 (en) Biomarkers for determining sensitivity of breast cancer cells to HER2-targeted therapy
CA2716826C (en) Drug selection for breast cancer therapy using antibody-based arrays
AU2010273319B2 (en) Drug selection for gastric cancer therapy using antibody-based arrays
US20140024548A1 (en) Drug selection for malignant cancer therapy using antibody-based arrays
US20120270745A1 (en) Drug selection for cancer therapy by profiling signal transduction proteins in ascites or pleural efflux samples
AU2013205274B2 (en) Drug selection for breast cancer therapy using antibody-based arrays
HK1185414B (en) Drug selection for breast cancer therapy using antibody-based arrays

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150504

FZDE Discontinued

Effective date: 20190226